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Abstract 
Background 
Calcium (Ca2+) handling proteins are known to play a pivotal role in the pathophysiology of 
cardiomyopathy. However little is known about early changes in the diabetic heart and the 
impact of insulin treatment (Ins). 
Methods 
Zucker Diabetic Fatty rats treated with or without insulin (ZDF ± Ins, n = 13) and lean 
littermates (controls, n = 7) were sacrificed at the age of 19 weeks. ZDF + Ins (n = 6) were 
treated with insulin for the last 6 weeks of life. Gene expression of Ca2+ ATPase in the 
cardiac sarcoplasmatic reticulum (SERCA2a, further abbreviated as SERCA) and 
phospholamban (PLB) were determined by northern blotting. Ca2+ transport of the 
sarcoplasmatic reticulum (SR) was assessed by oxalate-facilitated 45Ca-uptake in left 
ventricular homogenates. In addition, isolated neonatal cardiomyocytes were stimulated in 
cell culture with insulin, glucose or triiodthyronine (T3, positive control). mRNA expression 
of SERCA and PLB were measured by Taqman PCR. Furthermore, effects of insulin 
treatment on force of contraction and relaxation were evaluated by cardiomyocytes grown in 
a three-dimensional collagen matrix (engineered heart tissue, EHT) stimulated for 5 days by 
insulin. By western blot phosphorylations status of Akt was determed and the influence of 
wortmannin. 
Results 
SERCA levels increased in both ZDF and ZDF + Ins compared to control (control 100 ± 6.2 
vs. ZDF 152 ± 26.6* vs. ZDF + Ins 212 ± 18.5*# % of control, *p < 0.05 vs. control, #p < 0.05 
vs. ZDF) whereas PLB was significantly decreased in ZDF and ZDF + Ins (control 100 ± 2.8 
vs. ZDF 76.3 ± 13.5* vs. ZDF + Ins 79.4 ± 12.9* % of control, *p < 0.05 vs control). The 
increase in the SERCA/PLB ratio in ZDF and ZDF ± Ins was accompanied by enhanced Ca2+ 
uptake to the SR (control 1.58 ± 0.1 vs. ZDF 1.85 ± 0.06* vs. ZDF + Ins 2.03 ± 0.1* 
µg/mg/min, *p < 0.05 vs. control). Interestingly, there was a significant correlation between 
Ca2+ uptake and SERCA2a expression. As shown by in-vitro experiments, the effect of 
insulin on SERCA2a mRNA expression seemed to have a direct effect on cardiomyocytes. 
Furthermore, long-term treatment of engineered heart tissue with insulin increased the 
SERCA/PLB ratio and accelerated relaxation time. Akt was significantly phosphorylated by 
insulin. This effect could be abolished by wortmannin. 
Conclusion 
The current data demonstrate that early type 2 diabetes is associated with an increase in the 
SERCA/PLB ratio and that insulin directly stimulates SERCA expression and relaxation 
velocity. These results underline the important role of insulin and calcium handling proteins 
in the cardiac adaptation process of type 2 diabetes mellitus contributing to cardiac 
remodeling and show the important role of PI3-kinase-Akt-SERCA2a signaling cascade. 
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Introduction 
The sarcoplasmatic reticulum (SR) plays a pivotal role in the contraction and relaxation cycle 
of the heart by virtue of its ability to tightly regulate intracellular calcium (Ca2+) 
concentration. Myocardial contraction is initiated by Ca2+ entry through Ca2+ channels of 
the plasma membrane (L-type Ca2+ channel) [1] triggering the Ca2+ release from the SR 
through the ryanodine receptor. During diastole Ca2+ is transported from the cytoplasma into 
the SR by the SR Ca2 + ATPase (SERCA). Recent cloning analysis revealed three distinct 
genes encoding for SR Ca2 + ATPases (SERCA 1–3), of which the SERCA2a is 
predominately expressed in cardiac tissue [2]. SERCA2a activity depends on the amount of 
SERCA2a protein and is further regulated by its inhibitory protein phospholamban (PLB) [3]. 
SERCA2a is the major determinant of the beat-to-beat regulation of cardiac contraction, and 
overexpression of this protein in mice has been shown to enhance myocardial relaxation [4]. 
Unphosphorylated PLB inhibits the Ca2+ uptake of SERCA2a and phosphorylation of the 
protein disrupts the inhibitory interaction resulting in increased Ca2+ transport towards the 
SR. Recent studies on PLB knockout mice have underlined the importance of PLB as a key 
regulator of cardiac contraction and relaxation [5]. 
While diabetes leads to cardiomyopathy in later stages with hypocontractility and reduced 
SERCA activity [6], we have observed increased contractility in earlier stages of type 2 
diabetes mellitus [7]. Various animal models of diabetes have been used to study the causes 
and underlying subcellular events of diabetic cardiomyopathy. These studies suggest a 
dysfunctional sarcoplasmic reticulum (SR), leading to altered intracellular calcium handling 
in cardiac myocytes. This mechanism might be involved in the development of diabetic 
cardiomyopathy [6,8]. A reduced sequestration of calcium into the SR could readily explain 
the prolonged cardiac relaxation observed in diabetic cardiomyopathy. As a consequence, the 
SR calcium content declines, leading to a reduced systolic calcium release and therefore a 
weaker cardiac contraction. However, these studies were mainly carried out in models 
resembling insulin-dependent diabetes. Previous studies with diabetes type 1 models have 
shown a down-regulation of SERCA2a in the heart associated with a decrease in systolic and 
diastolic function. These functional alterations can be reversed by insulin treatment or 
SERCA2a overexpression [4,9]. So far, there is little information available on myocardial 
SERCA2a and PLB changes in the early stages of type 2 diabetes which is characterized by 
rather high insulin levels [8,10,11]. 
The Zucker Diabetic Fatty rat (ZDF/Drt-fa) is characterized by early onset of hyperglycemia, 
hyperphagia, hyperinsulinemia, adiposity and hyperlipidemia, thereby resembling the clinical 
features of human type 2 diabetes [12]. In an earlier study, we were able to demonstrate that 
animals in transition from insulin resistance to type 2 diabetes but not lean control rats 
develop significant myocardial hypertrophy associated with increased systolic function as 
evaluated by echocardiography [7]. These findings raised the possibility that one or more 
proteins regulating intracellular calcium homeostasis may be altered in these animals. 
Therefore, the present study was designed to determine whether the cardiac phenotype of 
ZDF rats is associated with alterations in cardiac SR function and expression of SERCA2a 
and its regulating protein PLB. Since insulin treatment is widely used as a therapeutic option 
for patients with poorly controlled type 2 diabetes, its impact on the aforementioned proteins 
was studied in isolated cell preparations of the heart. Furthermore, we investigated the 
functional consequences of high insulin levels in an innovative engineered heart tissue model. 
Materials and methods 
Animal model 
Male Zucker Diabetic Fatty rats (body weight (BW) range: 106–158 g, n = 13) and male 
Zucker lean rats (BW 85–118 g, n = 7) were obtained at the age of five weeks from Genetic 
Models (Indianapolis, USA). Animals were maintained on RMH-B rat chow from Hope 
Farms (Woerden, Netherlands) with water ad libitum. All animals were individually housed 
in a 12 h dark/light cycle controlled room. The protocol had been approved by the local 
committee on animal research and conforms to the Guide for the Care and Use of Laboratory 
Animals, published by the US National Institutes of Health (NIH Publication No. 85–23; 
revised 1985). At the age of 13 weeks, one week after developing hyperglycemia, the animals 
were divided into three groups: (1) Zucker lean rats (control group, n = 7), (2) Zucker 
Diabetic Fatty rats without insulin treatment (ZDF; n = 7), and (3) Zucker Diabetic Fatty rats 
treated with insulin (ZDF + Ins; n = 6). Insulin treatment (Actrapid HM U500, Novo Nordisk, 
Mainz, Germany) was initiated at a dose of 25.0 
U/kg/day with subcutaneously implanted Alzet osmotic minipumps (Model 2ML2 and 
2ML4, Charles River Wiga, Sulzfeld, Germany). Pumps were changed after 2 weeks and the 
insulin dose was adapted to normalize blood glucose levels. Body weight was determined 
every week, and blood glucose levels every 2–3 weeks (Accu-Chek Plus Roche, Mannheim, 
Germany). At the age of 18 weeks, systolic blood pressure and heart rate were measured by 
indirect tail-cuff method as described [13] using an automated cuff inflator-pulse detection 
system (W + W electronic AG, BP recorder No. 8005, Basel, Switzerland). After 6 weeks of 
insulin treatment, at the age of 19 weeks, the animals were killed. 
Tissue Pr0065paration 
Hearts were rapidly excised, rinsed with saline and blotted dry. The whole heart weight was 
determined. The heart was dissected free from the atria, cut into right and left ventricular 
tissue, frozen in liquid nitrogen within 3 minutes and stored at −80 C until analyzed, as 
described earlier [7]. 
Neonatal rat cardiac myocytes 
Rat cardiac myocytes were isolated from 1- to 3-day-old neonatal Wistar rats (University of 
Regensburg breed, from Charles River, Sulzfeld, Germany) as described earlier [14]. Briefly, 
hearts from 50–70 pups were minced and subjected to serial trypsin digestion to release 
single cells. After the final digestion, cells were washed and pre-plated for 1–2 h in complete 
culture medium (MEM supplemented with 10% fetal calf serum and 1% 
penicillin/streptomycin). Unattached cells were pelleted and suspended in culture medium 
containing 0.1 mmol/l 5´-bromo-2´-desoxyuridine (BrdU) to suppress overgrowth of non- 
myoctes. Cells were then plated on culture dishes at a density of 150,000 cells/cm2 and 
incubated for 5 days at 37°C before being stimulated with insulin (0.1-3.0 µmol/l), 
wortmannin (300 and 1000 nM) or triiodothyronine (3.0 nmol/l) as a positive control for up-
regulation of SERCA2a mRNA expression [15]. 
Engineered heart tissues 
Engineered heart tissues (EHT) were prepared as described previously [16]. Briefly, circular 
EHT were prepared by mixing freshly isolated cardiac myocytes from neonatal rats with 
collagen type 1 prepared from rat tails, a basement membrane mixture (Matrigel, tebu, 
Offenbach, Heidelberg, Germany), and concentrated serum containing culture medium 
(2xDMEM, 20% horse serum, 4% chicken embryo extract, 200 U/ml penicillin and 200 
µg/ml streptomycin); pH was neutralized by titration with NaOH (0,1 N). The reconstitution 
mix was pipetted into circular casting molds and incubated for 30 to 45 min at 37oC and 5% 
CO2 to allow hardening of the reconstitution mix. Thereafter, 5 ml serum-containing culture 
medium (DMEM, 10% horse serum, 2% chicken embryo extract, 100 U/ml penicillin and 
100 µg/ml streptomycin) was added to each dish. Culture was performed as described earlier 
[16]. After 7 days in culture, EHTs were transferred to a stretch device and subjected to 
phasic stretch (to 110% of their original length) for 5 days. Culture medium was changed 12 
hours after EHT casting and then every other day. After transfer to the stretch device, the 
culture medium was changed every day and supplemented with insulin at a high 
physiological concentration (0.1 µg/ml; Sigma-Aldrich, Taufkirchen, Germany). 
Force measurement 
After 12 days (7 days in casting molds and 5 days of stretching), the EHTs were transferred 
to thermostated organ baths containing gassed Tyrode´s solution and subjected to isometric 
force measurement as described elsewhere [16]. Briefly, electrically stimulated EHTs (2 Hz) 
were stretched to the length at which force of contraction was maximal and inotropic and 
lusitropic responses to cumulative concentrations of isoprenaline (0.1-1000 nM) in the 
presence of 0.2 mM calcium were recorded. Contractile activity was evaluated with a PC-
assisted system (BMON2, Ingenieurbüro Jäckel, Hanau, Germany). 
RNA analysis 
Total RNA from left ventricles or cultured cardiac myocytes was isolated with Trizol® 
(Canadian Life Technologies Inc., Burlington, Ontario, Canada) according to the 
manufacturer’s instructions. The concentration was determined photometrically at 260 nm. 
Total RNA was stored at 80°C. For Northern blot analysis 20 µg of total RNA were 
denatured, size-fractionated by electrophoresis on 1% agarose gels under denaturing 
conditions, transferred to nylon membranes (Gene Screen Plus, NEN, Dreieich, Germany) 
and immobilized by ultraviolet irradiation. Blots were prehybridized and hybridized using 
standard protocols as described previously [17]. Hybridized filters were washed and exposed 
at −80 C° to x-ray films (XAR-5, Eastman Kodak, N.Y., USA) by using intensifying screens. 
Different exposures of all autoradiograms were obtained to ensure that laser scanning 
(Personal Densitometer No. 50301, Molecular Dynamics) was performed within the linear 
range of densitometry. For hybridization cDNA probes for rat SERCA, PLB (kindly gifted by 
K.R. Boeheler) and GAPDH were radiolabelled with α32-P dCTP (specific activity 3000 
Ci/mmol, Amersham, Dreieich, Germany) for Northern blot analysis. Values were 
normalized to these house-keeping gene GAPDH. The rat cDNA of GAPDH was cloned by 
reverse transcriptase PCR using the following primers: forward 5´-
CTTCACCACCATGGAGAAGG-3´; and reverse 5´-ATTGAGAGCAATGCCAGCC-3´. 
For quantitative RT-PCR (qRT-PCR), total RNA was transcribed with SuperScriptII RT 
(Invitrogen, CA, USA). Individual samples of 20 ng cDNA were amplified with 
AmpliTaqGold Polymerase (Applied Biosystems, CA, USA) utilizing gene specific primers 
and fluorogenic probes (5’ FAM and 3’ TAMRA; see below for complete primer/probe 
sequence information) in an ABI PRISM® 7900HT Sequence Detection System (Applied 
Biosystems). Probes were designed to cross exon/intron boundaries with primer annealing 
sites being located in the adjacent exons to eliminate the possibility of genomic DNA 
amplification. . Standard curves were performed in duplicate with serially diluted cDNA from 
neonatal rat heart tissue (1.5 - 50 ng) to determine PCR efficiency, which was similar in all 
groups SERCA and Phospholamban expression were evaluated as SERCA/PLB ratio and 
correlated to EHT twitch tension and relaxation time (T2). Quantification was performed by 
the standard curve and 2-∆∆Ct methods [18]. 
SERCA2a: forward primer 5´- AGT GGC TGA TGG TGC TGA AA-3´ 
reverse primer 5´- GCA CCC GAA CAC CCT TAC AT-3 
probe 5´ FAM- TTA CTC CAG TAT TGC AGG CTC CAG GTA -TAMRA 3´ 
PLB: forward primer 5´- GCA GCT GAG CTC CCA GAC TT-3 
reverse primer 5´- TTT CCA TGA TGC CAG GAA GAC-3´ 
probe 5´ FAM- CAC AGA AGC CAA GGC CTC CTA AAA GGA G -TAMRA 3´ 
We checked 18 S, GAPDH, and CSQ2 (data not shown). However, corrections are not 
necessary because we have determined PLB and SERCA from the same cDNA samples. 
Western blot analysis 
20 µl of cell suspension of the cardiomyocyte cell culture were separated on 10% SDS-
polyacrylamide gels. Gels were run andseparated proteins were transferred to nitrocellulose 
membranes in 50 mM sodium phosphate buffer, pH 7.4, for 20 h at 300 mA, and 4°C. 
Nitrocellulose sheets were incubated with a rabbit polyclonal anti-human antisera (Sigma) at 
a 1:2000 dilution. Phospho-Akt and Akt antibodies (1:1000, from New England Biolabs) 
were visualized colorimetrically by using horseradish peroxidase- (HRP) conjugated goat 
anti-rabbit immunoglobulin G at a 1:1000 dilution. After phospho-Akt blotting, the blot was 
stripped for 30 min at 50oC and then blotted for Akt, serving also as loading control. 
Apparent molecular weights were determined by using a prestained standard (kaleidoscope 
prestained standard, Biorad, USA). 
Oxalate-supported Ca2+ uptake 
Oxalate-supported SR Ca2+ uptake was measured in left ventricular homogenates as 
described previously [19]. Briefly, the Ca2+ uptake medium of 0.2 ml contained 40 mmol/l 
imidazole (pH 7.0), 100 mmol/l KCl, 5 mmol/l MgCl2, 5 mmol/l TrisATP, 6 mmol/l 
phosphocreatine, 10 mmol/l K + -oxalate, 10 mmol/l NaN3, 10 µM synthetic protein kinase 
A-inhibitor peptide [PKI(6–22)amide; GIBCO-BRL, Eggenstein, Germany], 0.2 mmol/l 
EGTA, and 0.08 or 0.250 mmol/l 45CaCl2 corresponding to 0.34 or 3.68 µmol/l free Ca2+, 
respectively After 2 min of preincubation at 37°C, the measurement was started by addition 
of homogenate (30 µg protein) and 2 min later a 0.15-ml sample was filtered through 0.45- 
µm Millipore filters using a vacuum pump. The filter was immediately washed twice with 3 
ml ice-cold solution containing 100 mM KCl, 2 mM EGTA, and 40 mM imidazole (pH 7.0). 
Radioactivity bound to dry filters was determined by liquid scintillation counting. All 
measurements were done in duplicate Ca uptake was measured within the linear range of the 
reaction. Calculated Ca2+ uptake values were expressed as nmoles of Ca2+ per mg of protein 
per min or µmoles of Ca2+ per g wet LV wt min. 
Statistics 
Statistical analysis was performed using GraphPad PRIZM 5.0. Results are expressed as 
mean ± SEM. Comparisons between multiple groups were assessed by one-way analysis 
ANOVA-test and post-hoc analysis by Bonferroni. The strength of the relationship between 
two variables was assessed by calculating the product–moment correlation coefficient r. 
Statistical significance was accepted at p < 0.05. 
Results 
Diabetic animals 
The ZDF rats developed a manifest diabetes at the age of 12 weeks (Capillary Glucose 
control group 78 ± 1.8 mg/dl vs. ZDF 252 ± 39* mg/dl vs. ZDF + Ins 292 ± 33* g/dl*, p < 0.05 
vs. control). Body weight in ZDF rats increased steadily over time compared to non-diabetic 
lean animals. Treatment with insulin led to a further increase in body weight three weeks 
after beginning treatment (see Table 1). Absolute heart weight was significantly higher in the 
treatment group, but not in non-treated ZDF rats compared to age- matched ZDF rats (see 
Table 1). As expected, treatment with insulin decreased blood glucose level towards 
normoglycemic values in diabetic animals (see Table 1). Plasma C-peptide-levels were 
markedly elevated in diabetic ZDF rats indicating severe hyperinsulinemia. Interestingly, 
heart rate was significantly lower in all diabetic animals and blood pressure was the same in 
the non-treated ZDF group and even reduced in the insulin-treated ZDF group (at 19 weeks 
of age: control 484± min-1 vs. ZDF 416 ± 13* min-1 vs. ZDF + Ins 421 ± 18* min-1, 
*p < 0.05 vs. control) 
Table 1 Biometric data at 19 weeks 
Characteristics Control (n = 7) ZDF (n = 7) ZDF + Ins (n = 6) 
BW (g) 353 ± 11 402 ± 9* 478 ± 25* 
HW (mg) 1372 ± 33 1341 ± 46 1530 ± 53# 
Rel. HW (mg/g BW) 4.1 ± 0.2 3.3 ± 0.1* 3.2 ± 0.4* 
Serum glucose 96 ± 7 477 ± 26* 251 ± 73* 
C-peptide (pmol/l) 593 ± 98 913 ± 65* 639 ± 162# 
Hb1Ac (% of control) 100 ± 4 301 ± 12* 179 ± 19*# 
ZDF = Zucker Diabetic Fatty rats, Ins = insulin, BW = body weight, HW = heart weight 
*p < 0.05 vs control and #p < 0.05 vs. ZDF 
Expression levels of SERCA and phospholamban (PLB) 
SERCA2a detected a single mRNA of about 4.0 kb. The PLB probe hybridized with two 
mRNA species of approximately 3.0 and 1.3 kb (Figure 1A). As shown in Figure 1B 
SERCA2a mRNA levels were significantly higher in diabetic compared to non-diabetic 
animals and showed a trend towards a further in crease in insulin-treated animals (both 
p < 0.05 vs control). In contrast PLB mRNA levels were significantly reduced both in ZDF 
and ZDF + Ins (both p < 0.05 vs control). This led to an increase in the relative 
SERCA2a/PLB ratio (Figure 1c), indicating a facilitated intracellular calcium reuptake. 
Interestingly, treatment with insulin led to a further increase in SERCA2a mRNA in diabetic 
animals. To determine whether insulin directly up-regulates SERCA2a mRNA, isolated 
cardiac myocytes were treated with insulin over 5 days. As expected triiodothyronine 
(positive control) increased SERCA2a mRNA levels by approximately 75% as assessed by 
quantitative RT-PCR and had no effect on PLB expression (Figure 2A). Insulin led to a 
concentration-dependent increase in SERCA2a and PLB Fredersdorf et al. - Expression of SR 
Ca++ − uptake regulating proteins in the diabetic heart 11 expression (Figure 2B). 
Interestingly, SERCA2a expression was already increased at lower insulin concentrations 
(0.1–0.3 µmol/L) whereas PLB was unchanged. However, at higher insulin concentrations we 
found a similar increase in SERCA2a and PLB expression. 
Figure 1 In vivo data: Expression of SERCA 2a and PLB in left ventricular tissue from 
non-diabetic control rats (n = 7), Zucker Diabetes Fatty (ZDF) rats (n = 7) and ZDF 
(n = 6) rats treated with insulin. (A) Shows a representative Northern blot of SERCA and 
phospholamban (lane 1 = left ventricular tissue from control rats, lane 2 = left ventricular 
tissue from diabetic ZDF rats; lane 3 = left ventricular tissue from ZDF rats treated with 
insulin). Arrow depicts the position of the 28 S ribosomal RNA. (B) quantitative analysis and 
(C) SERCA2a/PLB ratio. Values are given in mean ± SEM. *p < 0.05 vs. control; #p < 0.05 
vs. ZDF 
Figure 2 In vitro data: (A) Effect of triiodothyronine (T3; 3.0 nmol/l) and (B) increasing 
concentrations of insulin on SERCA2a and PLB mRNA expression in isolated cardiac 
myocytes assessed by RT-PCR. T3 was used as positive control. N = 9 in each group from 
three independent experiments. Values are given as mean ± SEM. *p < 0.05 vs. control (A), 
*p < 0.05 vs. no insulin (B) 
Ca2 + −transport of myocardial sarcoplasmatic reticulum 
To test whether the aforementioned changes in SERCA2a and PLB affect Ca2+ uptake of the 
sarcoplasmatic reticulum we measured oxalate-supported Ca2+ uptake in homogenates from 
left ventricular tissue of diabetic and non-diabetic animals. Ca2+ uptake was significantly 
higher in diabetic animals compared to non-diabetic animals (Figure 3A). Treatment with 
insulin further augmented Ca2+ uptake. As shown in Figure 3B there was a close relationship 
between myocardial SERCA2a mRNA expression and the calcium transport rate supporting 
the notion that insulin directly modifies SERCA2a mRNA expression in the heart. 
Figure 3 In vivo data: Differences in sarcoplasmic reticular Ca2+ uptake in left 
ventricular homogenates prepared from (A) non-diabetic control rats (control) (n = 7), 
Zucker Diabetes Fatty (ZDF) rats (n = 7) and ZDF rats treated with insulin (ZDF + Ins, 
n = 6). (B) Relationship between calcium uptake and myocardial SERCA2a/PLB mRNA 
ratio. Ca2+ uptake was measured for 2 min in the presence of 3.68 µM free Ca2+ 
concentrations. Values are given as mean ± SEM. *p < 0.05 vs. control 
Effect of insulin on myocardial function in vitro 
Engineered heart tissue (EHT) chronically stimulated (5 days) with insulin in a supra-
physiological concentration (0.1 µg/mL) revealed a significant increase in the SERCA2a/PLB 
ratio as determined by quantitative RT-PCR (Figure 4 A). 
Figure 4 In vitro data: Effect of insulin on SERCA2a/PLB mRNA ratio (A) and (B) 
EHT relaxation data (T2) . EHT were stimulated for 5 days with 0.10 µg/mL insulin over 5 
days (n = 7-10) in each group from two independent cell preparations. Transcript 
concentration was determined by mRNA was measured by quantitative RT-PCR. *p < 0.01 
vs. EHT. (C) Correlation between relaxation time and SERCA2a/PLB ratio in EHT´s without 
and with prior stimulation of insulin. Contractile response of isoprenaline (1 µmol/L) was 
determined under isometric conditions and in the presence of 0.2 mmol/L calcium (n = 7-8 in 
each group from two independent cell preparations). For clarity, only mean values ± SEM of 
the two groups are shown. *p < 0.05 vs. non insulin treated EHTs. In (B) relaxation time (T2) 
was significantly shorter in insulin stimulated EHTs (p < 0.05) 
To determine the influence of the observed changes in the SERCA2a/PLB ratio on 
myocardial function contractile parameters of electrically driven control EHTs and insulin-
stimulated EHTs were measured. Isometric force development at optimal length in the 
absence (0.75 ± 0.12 vs. 0.78 ± 0.11 mN, n = 7 + 10; p = NS) and presence (1.32 ± 0.13 vs. 
1.42 ± 0.08 mN, n = 7 + 10; p = NS) of isoprenaline (1 µmol/L) was not significantly different 
between control EHTs and insulin-stimulated EHTs (EHT 1.32 ± 0.13 vs. EHT + Ins 
1.4 ± 0.14 mN p = NS). Interestingly, EHT relaxation (T2) was shorter in insulin treated EHTs 
(sustained positive lusitropic effect) under baseline conditions (EHT 105 ± 3 ms vs. EHT + Ins 
92 ± 4 ms, n = 8-10; p < 0.05 vs. EHT) and under maximal isoprenaline stimulation (EHT 
88 ± 2 ms vs. EHT + Ins 78 ± 2 ms, n = 8-10; p < 0.05 vs EHT; Figure 4B). In contrast, time to 
peak contraction was not affected by chronic insulin stimulation (data not shown). 
Ultimately, the sustained lusitropic effect of insulin of isoprenaline as depicted in Figure 4B 
was considerably enhanced in EHTs treated with insulin compared to control EHTs. 
Interestingly, there was a significant correlation between the isoprenaline induced relaxation 
and the higher SERCA2a/PLB ratio (Figure 4C). The latter was the result of a higher 
SERCA2a concentration and at the same time lower PLB transcript concentration Notably, 
absolute PLB transcript abundance was markedly lower in insulin treated EHTs when 
compared to control EHTs. 
Effect of insulin on akt 
As shown by Figure 5, Akt was significantly phosphorylated by insulin (B) in 
cardiomyocytes. Unphosphorylated Akt blot served as control (A). This effect could be 
abolished by wortmannin (C) at higher wortmannin concentrations (1000 nM) for every 
insulin stimulation, at lower wortmannin concentration (300 nM) only for lower insulin 
concentrations. 
Figure 5 Effect of increasing concentrations of insulin on the phosphorylation status of 
Akt in isolated cardiomyocytes. (A) Western blot incubated with a specific antibody 
directed to total Akt. (B) The identical Western blot incubated with a specific antibody 
directed to phospho-Akt (Ser473). The insulin- mediated increase of phosphorylated Akt was 
abolished by the administration of an intermediated concentration of the PI3K-Inhibitor 
Wortmaninn, where Wortmaninn per se had no effect on phospho-Akt (C) 
Discussion 
The key findings of this study are that in the early stages of type 2 diabetes, myocardial 
expression of SERCA2a is markedly elevated, whereas the expression of PLB mRNA is 
reduced. These changes go along with a significant increase in sarcoplasmatic Ca2+ uptake. 
Interestingly, the SERCA/PLB ratio in diabetic animals was further increased by insulin 
treatment. In vitro, we were able to demonstrate that insulin treatment of isolated cardiac 
myocytes led to a concentration-dependent increase in SERCA2a expression. This effect was 
also seen in a more complex model of engineered heart tissue and correlated positively with 
cardiac relaxation in vitro. . In addition, Akt was significantly stimulated by insulin in 
cardiomyocyte cell culture. This approach allows us to directly determine contractile 
alterations caused by insulin treatment without considering insulin-related systemic changes 
which might also affect the cardiovascular system. However we must consider that in vitro 
data can not totally be compared to in vivo data. Nevertheless they give essential additional 
information. Together, this suggests that insulin, which is particularly elevated in premature 
type 2 diabetes mellitus, may be involved in the induction of SERCA2a mRNA expression 
and may be an early step in the pathogenesis of diabetic cardiomyopathy. 
Alterations of SERCA, PLB and ca uptake in diabetes mellitus 
Diastolic relaxation of the heart is mediated to a large extent by the uptake of Ca2+ into the 
sarcoplasmic reticulum. Several studies have shown that diabetic cardiomyopathy is 
associated with decreased contractility and impaired relaxation [19]. These changes have 
been attributed to a reduced ability to sequester calcium into the SR, which primarily 
determines the speed of cardiac relaxation. Consecutive experiments have shown that 
SERCA2a mRNA expression, protein level and activity is down-regulated in streptozotocin-
induced (STZ) type 1 diabetes mellitus [10,11]. In another model Wold and co-workers 
demonstrated in cardiomyocytes of rats with sucrose-induced insulin resistance that impaired 
SERCA activity with normal protein content contributes to cardiomyocyte dysfunction, 
whereas NCX function and expression are normal [20]. The authors concluded that subtle 
changes in Ca2+ regulation which occur prior to overt ventricular dysfunction and/or failure, 
may be common to early stages of a number of disorders involving insulin resistance. 
Furthermore, it has been demonstrated that reduced Ca2+ signaling in vascular smooth 
muscle cells from diabetic animals is related to a decline and/or redistribution in the IP3R 
Ca2+ channels and SERCA proteins. These changes could be repeated in cell culture 
experiments with high glucose levels [21]. The mechanism of alteration of SR proteins in 
STZ- induced diabetes, however, is unclear at present. The same is true for the Otsuka-Long-
Evans Tokushima Fatty rats (OLETF), a type 2 diabetes model. Here in late stages of 
diabetes, after additional sucrose feeding, the ventricular relaxation rate was significantly 
slower and was associated with reduced SERCA2a level [22]. These experiments are 
therefore in apparent contrast to our results. This discrepancy is most likely due to the 
different models used and the rather advanced duration of the diabetes and older age (60 
weeks in the latter experiments as compared to 19-week-old diabetic rats in our study). 
OLETF rats present a milder form of diabetes mellitus with later onset and milder 
hyperglycemia at the beginning [23]. We examined ZDF rats at earlier diabetic stages, and 
our previous experiments have shown that C-peptide levels are high at this age [7]. 
Insulin directly up-regulates SERCA and preserves cardiac function 
Most of the previous studies used a model with type 1 diabetes which differs fundamentally 
in pathophysiology. Whereas type 1 diabetes mellitus results from selective destruction of the 
insulin- producing beta cells of the pancreas, type 2 diabetes is primarily characterized by 
insulin resistance followed by progressive beta-cell dysfunction, resulting in low insulin 
levels in the long term. As recently shown, obese ZDF rats are insulin-resistant and have 
basal hyperinsulinemia that is due mainly to hypersecretion of insulin, as indicated by their 
elevated basal C-peptide levels [7,24]. Obese pre- diabetic and diabetic rats also show a 
reduction in insulin clearance, as indicated by their lower C- peptide/insulin ratio. 
Interestingly, the decrease in SERCA2a activity in STZ-treated rats can be reversed by 
insulin treatment [9,11], suggesting a direct stimulatory effect of insulin on SERCA2a. This 
hypothesis is further supported by other experiments demonstrating an up-regulation of 
SERCA1 in skeletal muscle after stimulation with insulin [1]. These observations 
demonstrate a possible link between insulin and expression of SR calcium ATPase, which is 
further confirmed by the present in vitro studies showing a direct effect of insulin on 
SERCA2a transcription in isolated cardiac myocytes. The important role of insulin for heart 
function is further supported by Kim et al., who showed that insulin preserves heart function 
in streptozotocin-induced diabetic heart failure with and without transplantation of smooth 
muscle cells [25]. 
In this context it has been shown that transgenic (TG) mice with cardiac-specific 
overexpression of active Akt not only exhibit hypertrophy and enhanced left ventricular 
function but also show a 6.6-fold increase in SERCA2a protein levels, which could be 
recapitulated in vitro by adenovirus-mediated overexpression of Akt in cultured adult 
ventricular myocytes [26]. We demonstrated on isolated cardiac myocytes a strong and rapid 
phosphorylation of Akt after stimulation with insulin. Conversely, inhibiting SERCA2a with 
either ryanodine or thapsigargin affected myocyte contraction and relaxation and Ca2+ 
channel kinetics more in TG than in WT. Thus, myocytes from mice with overexpressed Akt 
demonstrated enhanced contractility and relaxation, Fura-2 Ca2+ transients, and Ca2+ 
channel currents [26]. Furthermore, increased protein expression of SERCA2a plays an 
important role in mediating enhanced left ventricular function by Akt. Interestingly, insulin 
stimulation led to a significant increase in SERCA2a, co-immunoprecipitated with insulin 
receptor substrate proteins (IRS-1 and IRS-1) in isolated cardiac muscle demonstrating a link 
between insulin, insulin receptor and SERCA2a [27] in cardiac tissue. 
Recent experiments showed that insulin-like growth factor 1 (IGF-1) activates multiple 
signaling pathways, which involve the activation of the phosphatidylinositol (PI)3-kinase and 
Akt [28]. It is well known that the PI3-kinase-Akt cascade modulates diverse cellular 
functions. Furthermore, it has been shown that that IGF-I caused increases in myocyte 
contraction and relaxation function, increases in intracellular Ca2+ transients, and an 
upregulation of SERCA2a [29]. The same group demonstrated that transgenic mice with 
cardiac-specific overexpression of Akt showed an enhanced left ventricular function, 
associated with an increased expression of SERCA2a [30]. These data are in accord with the 
studies of von Lewinski and co-workers [31] (4), who suggested that Akt contribute to the 
acute inotropic effect of IGF-I in myocytes from human failing hearts. 
In the present study, the insulin induced increase in phosphorylated Akt in isolated 
cardiomyocytes was abolished by the PI3-kinase inhibitor wortmannin, which provided 
evidence for a role of PI3-kinase. This finding suggests that the underlying cellular 
mechanism for up regulation of SERCA2a is mediated by the PI3-kinase-Akt-SERCA2a 
signaling cascade. 
From a pathophysiological point of view, insulin-induced up-regulation of myocardial 
SERCA2a may be seen as a feedback mechanism in handling the volume overload caused by 
high glucose levels in the early phase of type 2 diabetes, when insulin levels are high. With 
progression of the disease and decreasing levels of insulin the expression of SERCA2a in the 
heart becomes impaired. The reduction of SERCA2a, as typically seen in the late phase of 
type 2 diabetes, is a major cause of reduced diastolic and systolic function of the heart. This 
hypothesis is reinforced by the findings of Sakata et al. who demonstrated that cardiac 
SERCA2a gene transfer restores systolic and diastolic function to normal in diabetic rats [8]. 
Furthermore, in-vitro experiments provide evidence that high glucose levels also impair 
cytosolic Ca2+ removal involving slowed SR Ca2+ uptake. It has been speculated that 
slowed SR Ca2+ uptake results from depressed protein kinase A (PKA) down-regulating 
SERCA2a, rather than through depressed SERCA expression. Both expression and function 
of the Na-Ca-exchanger (NCX) appear to be normal in these experiments [16]. In summary, 
the up-regulation of SERCA2a in the early phase of type 2 diabetes is an important 
physiological adaptation of the heart allowing it to handle volume overload caused by high 
glucose levels. 
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